12,372 trials
Acquired Immunodeficiency Syndrome · HIV Infections
Primary: Percentage of Participants With HIV-1 RNA < 50 Copies/mL at Week 48 of the Double-Blind Phase as Determined by the US FDA-Defined Snapshot Algorithm — 87.2; 80.8…
Erythema · Rosacea
Primary: Percentage of Patients With at Least a 2-Grade Decrease From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point…
Non-squamous Non-small Cell Lung Cancer
Primary: Progression Free Survival — 4.8; 6.8 months — p=0.0583
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants
Friedreich's Ataxia
Primary: Patient Assessment of Treatment Assignment: Comparison of the Proportions of Patients Randomised to Idebenone and Placebo Who Assessed That They Received Idebenone — 6…
Weight Loss
Primary: Mean Change in Body Weight From Baseline to Week 12 — 3.53; 0.14 kilogram (kg)
Intestinal Diseases
Primary: PID From Pre-dose Baseline at 20 Minutes After First Injection. — -4.09; -3.66 Units on a scale — p=<0.0001
Bleeding Peptic Ulcer
Primary: Rate of Clinically Significant Rebleeding Within 72 Hours — 107; 101; 1; 6 participants
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Peak Forced Expiratory Volume in One Second (FEV1) at Week 24 — 1.655; 1.562 Liters — p=<0.001
Arterial Thromboembolic Events · Atrial Fibrillation
Primary: Number of Arterial Thromboembolic Events — 2; 3; 2; 0 Arterial thromboembolic events
Vitamin D Deficiency
Primary: Number of Participants Who Develop Hypercalcemia — 0; 2 participants
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at to End of Study — -7.63; -7.94 millimeter(s) of mercury (mmHg) — p=0.0040
Conjunctivitis, Allergic
Primary: Ocular Itching Score — 0.33; 1.48; 0.29 score on a scale
Leukemia, Myelocytic, Acute · Leukemia, Lymphocytic, Acute · Leukemia, Myeloid, Chronic
Primary: Rate of Grades II-IV Acute GVHD-free Survival — 67; 62 percentage of participants
Radiation-induced Dermatitis
Primary: Mean Radiation Dermatitis Severity Score — 2.02; 1.99 units on a scale — p=0.6555